NAV3 and cancer: The mutation of some of these genes according to literature, EGFR, TP53, ZFHX4 and MUC16, is characterised and correlated with potential cancer therapeutics (Qiu et al. 2019; Aithal et al. 2018, 16; Goodwin 2018), whereas others, RYR2, LRP1B and NAV3, are yet to be investigated (Wang et al. 2019; Carlsson et al. 2012).